Impact of spleen size and splenectomy on outcomes of allo-HSCT for myelofibrosis

Massive splenomegaly prior to allogeneic hematopoietic stem cell transplant (allo-HSCT) in patients with myelofibrosis is a frequent cause of concern and may be associated with poorer outcomes. Ibrahim Yakoub-Agha, MD, PhD, Lille University Hospital, Lille, France, describes a registry-based study conducted on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation (EBMT). The study investigated the impact of spleen size and splenectomy on outcomes of patients undergoing allo-HSCT as well as the role of splenectomy before allo-HSCT in the era of JAK-inhibitors. The results highlight the detrimental effect of massive splenomegaly in transplant outcomes and support the role of splenectomy for patients with myelofibrosis. This interview took place during the 3rd European CAR T-cell Meeting.